12/5
08:10 am
tovx
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer [Yahoo! Finance]
Medium
Report
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer [Yahoo! Finance]
12/5
08:00 am
tovx
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
High
Report
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
11/14
09:49 am
tovx
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (???, Tokkyocho, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes [Yahoo! Finance]
Low
Report
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (???, Tokkyocho, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes [Yahoo! Finance]
11/12
08:37 am
tovx
Theriva Biologics GAAP EPS of -$6.81 [Seeking Alpha]
Medium
Report
Theriva Biologics GAAP EPS of -$6.81 [Seeking Alpha]
11/12
08:00 am
tovx
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results
High
Report
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results
10/31
04:05 pm
tovx
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
High
Report
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
10/16
08:00 am
tovx
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
Medium
Report
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
10/3
09:17 am
tovx
Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients [Seeking Alpha]
Medium
Report
Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients [Seeking Alpha]
12/10
05:22 pm
tovx
Form S-1 Theriva Biologics, Inc.
Medium
Report
Form S-1 Theriva Biologics, Inc.
12/5
08:11 am
tovx
Form 8-K Theriva Biologics, Inc. For: Dec 05
High
Report
Form 8-K Theriva Biologics, Inc. For: Dec 05
11/20
04:43 pm
tovx
Form S-8 Theriva Biologics, Inc.
Low
Report
Form S-8 Theriva Biologics, Inc.
11/12
09:48 am
tovx
Form 10-Q Theriva Biologics, Inc. For: Sep 30
High
Report
Form 10-Q Theriva Biologics, Inc. For: Sep 30
11/12
09:26 am
tovx
Form 8-K Theriva Biologics, Inc. For: Nov 12
High
Report
Form 8-K Theriva Biologics, Inc. For: Nov 12
11/1
04:05 pm
tovx
Form 8-K Theriva Biologics, Inc. For: Oct 31
Medium
Report
Form 8-K Theriva Biologics, Inc. For: Oct 31
10/16
08:10 am
tovx
Form 8-K Theriva Biologics, Inc. For: Oct 16
Low
Report
Form 8-K Theriva Biologics, Inc. For: Oct 16
10/3
04:12 pm
tovx
Form SC 13G Theriva Biologics, Inc. Filed by: INTRACOASTAL CAPITAL, LLC
Medium
Report
Form SC 13G Theriva Biologics, Inc. Filed by: INTRACOASTAL CAPITAL, LLC
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register